Bruker (NASDAQ:BRKR) Lowered to “Sell” at ValuEngine

ValuEngine downgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning, ValuEngine reports.

Several other research firms have also issued reports on BRKR. Jefferies Financial Group increased their price target on shares of Bruker from $45.00 to $56.00 and gave the stock a buy rating in a research report on Friday, June 21st. Barclays reiterated a hold rating and set a $44.00 price target on shares of Bruker in a research report on Monday, June 24th. BTIG Research increased their price target on shares of Bruker to $57.00 and gave the stock a buy rating in a research report on Friday, June 21st. Needham & Company LLC set a $58.00 price target on shares of Bruker and gave the stock a buy rating in a research report on Friday, September 27th. Finally, BidaskClub lowered shares of Bruker from a buy rating to a hold rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. Bruker presently has an average rating of Hold and a consensus price target of $49.90.

Shares of NASDAQ:BRKR traded up $0.32 on Wednesday, reaching $44.27. 729,442 shares of the company’s stock were exchanged, compared to its average volume of 680,407. The company has a fifty day moving average of $42.87 and a 200-day moving average of $43.17. Bruker has a twelve month low of $26.10 and a twelve month high of $51.41. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of 31.62, a PEG ratio of 2.19 and a beta of 1.39. The company has a current ratio of 2.19, a quick ratio of 1.27 and a debt-to-equity ratio of 0.63.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, August 1st. The medical research company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. Bruker had a net margin of 9.57% and a return on equity of 27.10%. The firm had revenue of $490.20 million for the quarter, compared to analyst estimates of $477.70 million. During the same quarter in the prior year, the business posted $0.25 EPS. The business’s revenue was up 10.5% compared to the same quarter last year. As a group, equities research analysts forecast that Bruker will post 1.61 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Tuesday, September 3rd were given a dividend of $0.04 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.16 annualized dividend and a dividend yield of 0.36%. Bruker’s dividend payout ratio is 11.43%.

In other Bruker news, VP Mark Munch sold 47,203 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $42.87, for a total value of $2,023,592.61. Following the sale, the vice president now owns 96,063 shares in the company, valued at $4,118,220.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Burkhard Prause sold 15,702 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $42.96, for a total transaction of $674,557.92. Following the completion of the sale, the chief executive officer now owns 1,338 shares in the company, valued at approximately $57,480.48. The disclosure for this sale can be found here. Company insiders own 26.50% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its stake in shares of Bruker by 0.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 29,691,185 shares of the medical research company’s stock valued at $1,483,075,000 after acquiring an additional 180,171 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Bruker by 1.5% during the second quarter. Vanguard Group Inc. now owns 10,866,673 shares of the medical research company’s stock valued at $542,789,000 after acquiring an additional 156,591 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Bruker by 1.1% during the second quarter. Janus Henderson Group PLC now owns 3,335,079 shares of the medical research company’s stock valued at $166,587,000 after acquiring an additional 36,643 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in shares of Bruker by 1.2% during the second quarter. D. E. Shaw & Co. Inc. now owns 1,924,095 shares of the medical research company’s stock valued at $96,109,000 after acquiring an additional 22,812 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Bruker by 2,436.8% during the second quarter. Invesco Ltd. now owns 1,698,456 shares of the medical research company’s stock valued at $84,838,000 after acquiring an additional 1,631,502 shares during the last quarter. Hedge funds and other institutional investors own 66.59% of the company’s stock.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Further Reading: Buyback For Investors Defined

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.